Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation in support of vaccine development.
Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.
The viral challenge agent, an Omicron variant SARS-CoV-2 virus manufactured by Naobios for the foundation, will be used to conduct a Controlled Human Infection Model (CHIM) study. The aim is to support the development of low-cost effective mucosal vaccines to stop respiratory virus transmission, which, with greater breadth, can be deployed to outbreak areas, typically in low-to-middle income countries (LMICs), to prevent widespread transmission.
The manufacture of Naobios’ viral challenge agent will be followed by stability testing for a period of three years.
“Naobios is excited to receive support from the Bill & Melinda Gates Foundation in its drive to accelerate the development and commercialisation of novel vaccines and the sustainable manufacture of existing vaccines,” said Eric Le Forestier, General Manager at Naobios. “With our experienced team, BSL3 suite and track record in successfully manufacturing several viral strains of challenge agents, we look forward to delivering on this project.”